101 related articles for article (PubMed ID: 21557716)
1. Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid.
Iqbal J; Vigl C; Moser G; Gasteiger M; Perera G; Bernkop-Schnürch A
Drug Deliv; 2011 Aug; 18(6):432-40. PubMed ID: 21557716
[TBL] [Abstract][Full Text] [Related]
2. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
3. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
4. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition.
Ling G; Zhang P; Zhang W; Sun J; Meng X; Qin Y; Deng Y; He Z
J Control Release; 2010 Dec; 148(2):241-8. PubMed ID: 20727928
[TBL] [Abstract][Full Text] [Related]
5. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles.
Yuan H; Jiang SP; Du YZ; Miao J; Zhang XG; Hu FQ
Colloids Surf B Biointerfaces; 2009 May; 70(2):248-53. PubMed ID: 19185474
[TBL] [Abstract][Full Text] [Related]
6. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
He W; Horn SW; Hussain MD
Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249
[TBL] [Abstract][Full Text] [Related]
7. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
Italia JL; Bhatt DK; Bhardwaj V; Tikoo K; Kumar MN
J Control Release; 2007 Jun; 119(2):197-206. PubMed ID: 17399839
[TBL] [Abstract][Full Text] [Related]
8. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Hintzen F; Perera G; Hauptstein S; Müller C; Laffleur F; Bernkop-Schnürch A
Int J Pharm; 2014 Sep; 472(1-2):20-6. PubMed ID: 24879935
[TBL] [Abstract][Full Text] [Related]
10. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
[TBL] [Abstract][Full Text] [Related]
11. Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system.
Deutel B; Greindl M; Thaurer M; Bernkop-Schnürch A
Biomacromolecules; 2008 Jan; 9(1):278-85. PubMed ID: 18159930
[TBL] [Abstract][Full Text] [Related]
12. Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide.
Iqbal J; Shahnaz G; Perera G; Hintzen F; Sarti F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2012 Jan; 80(1):95-102. PubMed ID: 21964316
[TBL] [Abstract][Full Text] [Related]
13. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms.
Santander-Ortega MJ; Jódar-Reyes AB; Csaba N; Bastos-González D; Ortega-Vinuesa JL
J Colloid Interface Sci; 2006 Oct; 302(2):522-9. PubMed ID: 16887138
[TBL] [Abstract][Full Text] [Related]
14. A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles.
Hu Q; van Gaal EV; Brundel P; Ippel H; Hackeng T; Rijcken CJ; Storm G; Hennink WE; Prakash J
J Control Release; 2015 May; 205():98-108. PubMed ID: 25583642
[TBL] [Abstract][Full Text] [Related]
15. The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery.
Millotti G; Perera G; Vigl C; Pickl K; Sinner FM; Bernkop-Schnürch A
Drug Deliv; 2011 Apr; 18(3):190-7. PubMed ID: 21039318
[TBL] [Abstract][Full Text] [Related]
16. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
Singh G; Pai RS
J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
18. Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles.
d'Angelo I; Parajó Y; Horváth A; Kéri G; La Rotonda MI; Alonso MJ
J Microencapsul; 2010; 27(1):57-66. PubMed ID: 19545221
[TBL] [Abstract][Full Text] [Related]
19. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
[TBL] [Abstract][Full Text] [Related]
20. Design and optimization of NSAID loaded nanoparticles.
Sashmal S; Mukherjee S; Ray S; Thakur RS; Ghosh LK; Gupta BK
Pak J Pharm Sci; 2007 Apr; 20(2):157-62. PubMed ID: 17416573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
